Mariner’s Carisma Therapeutics CARM Stock Holding History

Mariner’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-636	Closed	-$5K	–	2752
2022 Q3	$5K	Buy	+636	New	+$8.66K	﹤0.01%	2431

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BWA

Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mariner's CARM Position: Q4 2022 in Review

Mariner sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 636 shares — an estimated $5K sold.

Mariner first reported a position in CARM in Q3 2022 and held it in 1 quarter. The position peaked at $5K in Q3 2022. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

Mariner reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
Mariner sold 636 Carisma Therapeutics shares in Q4 2022, an estimated $5K.
Mariner first reported a position in Carisma Therapeutics in Q3 2022 and held it in 1 quarter.
Mariner's Carisma Therapeutics position peaked at $5K in Q3 2022.
70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on Mariner's 13F filing for Q4 2022, filed 14 Feb 2023.